Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies

Cancer Chemotherapy and Pharmacology

Volumn 33, Issue 6, 1994, Pages 515-522

  Teicher, Beverly A ^a,b   Korbut, Timothy T ^a   Menon, Krishna ^a   Holden, Sylvia A ^a   Ara, Gulshan ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; COLLAGENASE INHIBITOR; CYCLOPHOSPHAMIDE; DIFLUNISAL; INDOMETACIN; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; MEFENAMIC ACID; MELPHALAN; MINOCYCLINE; PHENIDONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; LEWIS CARCINOMA; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANIMAL; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG SYNERGISM; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MINOCYCLINE; NEOPLASM TRANSPLANTATION; PYRAZOLES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0028265258     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00686511     Document Type: Article

References (74)

1. Urinary excretion of degradation products of prostacyclin and thromboxane is increased in patients with gestational choriocarcoma
2. Increased synthesis of prostacyclin and thromboxane in human ovarian malignancy
3. Are laminin binding sites on tumor cell surface involved in the indomethacin-induced sensitivity to natural cytotoxic cells?
4. Laminin surface binding sites and metastatic potential of 3LL tumor cells, increased by indomethacin
5. Could aspirin really prevent colon cancer
6. The effect of leukotriene synthesis inhibitors on hamster periodontitis
7. Nonsteroidal antiinflammatory drugs — differences and similarities
8. Regulation of arachidonic acid release in vascular endothelium Ca2+-dependent and-independent pathways
9. Prostaglandin and thromboxane synthesis by human intracranial tumors
10. Lung tumorigenicity of NNK given orally to A/J mice: its application to chemoprevention efficacy studies
11. Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth
12. Modulation of c- jun and jun-B messenger RNA and inhibition of DNA synthesis by prostaglandin E2 in Syrian hamster embryo cells
13. Mechanisms of inactivation of lipoxygenases by phenidone and BW 755C
14. Sulindac oxidation/reduction by microbial cultures; microbial models of mammalian metabolism
15. Comparative disposition of sulindac and metabolites in five species
16. Inhibition of tumor growth and metastasis by chronic intravenous infusion of prostaglandin E1
17. Differential role of prostaglandin E1 on tumor metastasis
18. Sulindac suppression of colorectal polyps in Gardner's syndrome
19. Biological activities and mechanisms of action of PGJ2 and related compounds: an update
20. Relationship of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas
21. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin
22. Increase in radioresponse of murine tumors by treatment with indomethacin
23. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity
24. Tetracyclines inhibit human synovial collagenase in vivo and in vitro
25. A comparison of the anti-inflammatory activity of selective 5-lipoxygenase inhibitors with dexamethasone and colchicine in a model of zymosan induced inflammation in the rat knee joint and peritoneal cavity
26. The characteristic structural feature of the blood vessels of the Lewis lung carcinoma
27. Anaphylactic challenge causes eosinophil accumulation in bronchoalveolar lavage fluid of guinea pigs: modulation by betamethasone, phenidone, indomethacin, WEB 2086, and a novel antiallergy agent, SCH 37224
28. Cyclooxygenase gene expression is downregulated by heparin-binding (acidic fibroblast) growth factor-1 in human endothelial cells
29. Commentary. Prostacyclin and thromboxanes: implications for their role in tumor cell metastasis
30. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors
31. Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas
32. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors
33. Fatty acid cyclooxygenase metabolism of arachidonic acid in human tumor cells
34. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis
35. Prostacyclin and thromboxane in benign and malignant breast tumours
36. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice
37. Aspirin and the potential role of prostaglandins in colon cancer
38. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients
39. Dependence of indomethacin-induced potentiation of murine tumor radioresponse of tumor host immunocompetence
40. Improvement in therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus misonidazole
41. A protective effect of sulindac against chemically induced primary colonic tumours in mice
42. The effect of sulindac on colonic tumour formation in dimethylhydrazine-treated mice
43. Inhibition of purified glutathione S-transferases by indomethacin
44. Medical progress: clinical implications of prostaglandin and thromboxane A2 formation
45. Indomethacin modulation of monocyte cytokine release following pelvic irradiation for cancer
46. Inhibitors of collagenase IV and cell adhesion reduce the invasive activity of malignant tumour cells
47. Effects of long-term sulindac therapy on colonic polyposis
48. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects
49. Lung cancer
50. Tumor size dependence in the radiation response of the Lewis lung carcinoma
51. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat
52. Transforming growth factor-α-induced DNA synthesis and c- myc expression in primary rat hepatocyte cultures is modulated by indomethacin
53. The eicosanoids and their biochemical mechanisms of action
54. Influence of tumor size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumor
55. Combined radiotherapy-chemotherapy of Lewis lung carcinoma
56. Angiogenesis inhibition by minocycline
57. Cyclooxygenase inhibitors: in vitro and in vivo effects on antitumor alkylating agents in the EMT-6 murine mammary carcinoma
58. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II)
59. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis
60. Sulindac for polyposis of the colon
61. Prostaglandins, steroids and human mammary cancer
62. Indomethacin inhibition of glutathione S-transferases
63. Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma
64. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo
65. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice
66. Relationships between morphology, dissemination, migration, and prostaglandin E2 secretion by cloned variants of Lewis lung carcinoma
67. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors
68. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma
69. Effect of prostaglandin E2-producing nonmetastatic Lewis lung carcinoma cells on the migration of prostagladin E2-responsive metastatic Lewis lung carcinoma cells
70. Association of a functional prostaglandin E2-protein kinase A coupling with responsiveness of metastatic Lewis lung carcinoma variants to prostaglandin E2 and to prostaglandin E2-producing nonmetastatic Lewis lung carcinoma variants
71. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2
72. Diversity of melanoma plasma membrane proteinase: inhibition of collagenolytic and cytolytic activities by minocycline